Erythrocyte-based analgesic peptides

Regulatory Peptides

Volumn 180, Issue 1, 2013, Pages 58-61

  Song, Chang Zheng ^a   Wang, Qing Wei ^b   Song, Chang Cheng ^c  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesic peptide; Erythrocrine; Erythrocyte; Hemoglobin; Hemorphin; Proteasomal degradation

Indexed keywords

ANALGESIC AGENT; ERYTHROCRINE ANALGESIC PEPTIDE; HEMOGLOBIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL COMMUNICATION AND CELL CONTACT; CELL FUNCTION; ERYTHROCRINE; ERYTHROCYTE; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 84871920490     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.11.003     Document Type: Review

References (39)

1. Roux-Dalvai F., Gonzalez de Peredo A., Simo C., Guerrier L., Bouyssie D., Zanella A., et al. Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol Cell Proteomics 2008, 7:2254-2269.
2. Gomes I., Dale C.S., Casten K., Geigner M.A., Gozzo F.C., Ferro E.S., et al. Hemoglobin-derived peptides as novel type of bioactive signaling molecules. AAPS J 2010, 12:658-669.
3. Ciechanover A. The ubiquitin system: historical perspective. Proc Am Thorac Soc 2010, 7:11-12.
4. Song C., Wang Q., Li C.C. ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. J Biol Chem 2003, 278:3648-3655.
5. Neelam S., Kakhniashvili D.G., Wilkens S., Levene S.D., Goodman S.R. Functional 20S proteasomes in mature human red blood cells. Exp Biol Med (Maywood) 2011, 236:580-591.
6. Song C.Z., Wang Q.W., Liu H., Song C.C. Inhibition of intraerythrocytic proteasome retards the generation of hemorphins. Peptides 2012, 33:170-173.
7. Sipe J.D. Tissue engineering and reparative medicine. Ann N Y Acad Sci 2002, 961:1-9.
8. Gromov M. Crystals, proteins and isoperimetry. Bull Am Math Soc 2011, 48:229-257.
9. Cimen M.Y. Free radical metabolism in human erythrocytes. Clin Chim Acta 2008, 390:1-11.
10. Freitas R.A. Exploratory design in medical nanotechnology: a mechanical artificial red cell. Artif Cells Blood Substit Immobil Biotechnol 1998, 26:411-430.
11. Ivanov V.T., Karelin A.A., Yatskin O.N. Generation of peptides by human erythrocytes: facts and artifacts. Biopolymers 2005, 80:332-346.
12. Ivanov V.T., Karelin A.A., Blischenko E.Y., Philippova M.M., Nazimov I.V. Proteolytic degradation of hemoglobin in vivo. Role in formation of tissue specific peptide pool. Pure Appl Chem 1998, 70:67-74.
13. Nyberg F., Sanderson K., Glamsta E.L. The hemorphins: a new class of opioid peptides derived from the blood protein hemoglobin. Biopolymers 1997, 43:147-156.
14. Brantl V., Gramsch C., Lottspeich F., Mertz R., Jaeger K.H., Herz A. Novel opioid peptides derived from hemoglobin: hemorphins. Eur J Pharmacol 1986, 125:309-310.
15. Song C.Z., Wang Q.W., Song C.C. Diminution of hemoglobin-derived hemorphin: an underlying risk factor for cognitive deficit in diabetes. J Neurol Sci 2012, 317:157-158.
16. Philippova M.M., Khachin U.P., Sazonova O.V., Blishchenko E.Iu., Iatskin O.N., Nazimov I.V., et al. Fragments of functional proteins in a primary culture of human erythrocytes. Russ J Bioorg Chem 2008, 34:145-155.
17. Dale C.S., Pagano Rde L., Rioli V., Hyslop S., Giorgi R., Ferro E.S. Antinociceptive action of hemopressin in experimental hyperalgesia. Peptides 2005, 26:431-436.
18. Hallberg M. Targeting the insulin-regulated aminopeptidase/AT4 receptor for cognitive disorders. Drug News Perspect 2009, 22:133-139.
19. Davis T.P., Gillespie T.J., Porreca F. Peptide fragments derived from the beta-chain of hemoglobin (hemorphins) are centrally active in vivo. Peptides 1989, 10:747-751.
20. Song C., Rahim R.T., Davey P.C., Bednar F., Bardi G., Zhang L., et al. Protein kinase Czeta mediates micro-opioid receptor-induced cross-desensitization of chemokine receptor CCR5. J Biol Chem 2011, 286:20354-20365.
21. Glamsta E.L., Morkrid L., Lantz I., Nyberg F. Concomitant increase in blood plasma levels of immunoreactive hemorphin-7 and β-endorphin following long distance running. Regul Pept 1993, 49:9-18.
22. Blishchenko E.Y., Mernenko O.A., Yatskin O.N., Ziganshin R.H., Philippova M.M., Karelin A.A., et al. Neokyotorphin and neokyotorphin (1-4): secretion by erythrocytes and regulation of tumor cell growth. FEBS Lett 1997, 414:125-128.
23. Fukui K., Shiomi H., Takagi H., Hayashi K., Kiso Y., Kitagawa K. Isolation from bovine brain of a novel analgesic pentapeptide, neo-kyotorphin, containing the Tyr-Arg (kyotorphin) unit. Neuropharmacology 1983, 22:191-196.
24. Ueda H., Ge M., Satoh M., Takagi H. Non-opioid analgesia of the neuropeptide, neo-kyotorphin and possible mediation by inhibition of GABA release in the mouse brain. Peptides 1987, 8:905-909.
25. Vogel G. Nobel prizes. Gold medal from cellular trash. Science 2004, 306:400-401.
26. Zavrski I., Kleeberg L., Kaiser M., Fleissner C., Heider U., Sterz J., et al. Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des 2007, 13:471-485.
27. Goodman S.R., Kurdia A., Ammann L., Kakhniashvili D., Daescu O. The human red blood cell proteome and interactome. Exp Biol Med (Maywood) 2007, 232:1391-1408.
28. Kakhniashvili D.G., Bulla L.A., Goodman S.R. The human erythrocyte proteome: analysis by ion trap mass spectrometry. Mol Cell Proteomics 2004, 3:501-509.
29. Kisselev A.F., Akopian T.N., Woo K.M., Goldberg A.L. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem 1999, 274:3363-3371.
30. Fagan J.M., Waxman L., Goldberg A.L. Red blood cells contain a pathway for the degradation of oxidant-damaged hemoglobin that does not require ATP or ubiquitin. J Biol Chem 1986, 261:5705-5713.
31. Bross P.F., Kane R., Farrell A.T., Abraham S., Benson K., Brower M.E., et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004, 10:3954-3964.
32. Wheat L.M., Kohlhaas S.L., Monbaliu J., De Coster R., Majid A., Walewska R.J., et al. Inhibition of bortezomib-induced apoptosis by red blood cell uptake. Leukemia 2006, 20:1646-1649.
33. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639.
34. Willekens F.L., Bosch F.H., Roerdinkholder-Stoelwinder B., Groenen-Dopp Y.A., Werre J.M. Quantification of loss of haemoglobin components from the circulating red blood cell in vivo. Eur J Haematol 1997, 58:246-250.
35. Collinder E., Nyberg F., Sanderson-Nydahl K., Gottlieb-Vedi M., Lindholm A. The opioid haemorphin-7 in horses during low-speed and high-speed treadmill exercise to fatigue. J Vet Med A Physiol Pathol Clin Med 2005, 52:162-165.
36. Niscola P., Sorrentino F., Scaramucci L., de Fabritiis P., Cianciulli P. Pain syndromes in sickle cell disease: an update. Pain Med 2009, 10:470-480.
37. Song C., Wang Q., Li C.C. Characterization of the aggregation-prevention activity of p97/valosin-containing protein. Biochemistry 2007, 46:14889-14898.
38. Verhoef L.G.G.C., Lindsten K., Masucci M.G., Dantuma N.P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 2002, 11:2689-2700.
39. Jacob E. The pain experience of patients with sickle cell anemia. Pain Manag Nurs 2001, 2:74-83.